Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,950.84 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 6,404 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $10,950.84. Following the transaction, the senior vice president now directly owns 587,848 shares in the company, valued at $1,005,220.08. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $1.51 on Friday. Allogene Therapeutics, Inc. has a 52-week low of $1.50 and a 52-week high of $5.78. The stock has a fifty day moving average price of $2.01 and a two-hundred day moving average price of $2.43. The firm has a market capitalization of $316.60 million, a P/E ratio of -0.97 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Finally, Piper Sandler reduced their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Hedge Funds Weigh In On Allogene Therapeutics

Several institutional investors have recently added to or reduced their stakes in ALLO. Barclays PLC increased its holdings in shares of Allogene Therapeutics by 101.5% during the third quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after buying an additional 172,745 shares in the last quarter. Zacks Investment Management bought a new stake in Allogene Therapeutics during the 3rd quarter worth approximately $1,446,000. Geode Capital Management LLC increased its holdings in Allogene Therapeutics by 14.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after purchasing an additional 507,021 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Allogene Therapeutics by 70.3% in the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock worth $1,119,000 after purchasing an additional 198,231 shares in the last quarter. 83.63% of the stock is owned by institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).